Integrilin

Active Ingredient:: Eptifibatide
Origin:: EU

Integrilin (Eptifibatide)

Q: Who should not use Integrilin?

Integrilin is contraindicated in patients with active major bleeding, severe thrombocytopenia, known hypersensitivity to eptifibatide or any component of the formulation, and in those who have had a recent intracranial hemorrhage. Caution is also advised in severe renal impairment.

Eptifibatide, the active ingredient in Integrilin, is a glycoprotein IIb/IIIa inhibitor presented as an injection solution for intravenous use. It provides antiplatelet therapy for adults with unstable angina, non‑ST elevation myocardial infarction (NSTEMI) and during percutaneous coronary intervention (PCI) to reduce thrombotic complications.

GNH India supplies Integrilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required and regulatory support.

Manufacturer / TM Owner

Glaxosmithkline (Ireland) Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Integrilin (eptifibatide) is used as an antiplatelet agent in acute coronary syndromes and interventional cardiology.

Unstable angina: reduces the risk of progression to myocardial infarction by inhibiting platelet aggregation during the acute phase.
Non‑ST elevation myocardial infarction (NSTEMI): facilitates early reperfusion and limits thrombus growth when combined with standard therapy.
Percutaneous coronary intervention (PCI): prevents intra‑procedural and post‑procedural platelet clumping, decreasing the incidence of ischemic complications.

How It Works

Eptifibatide acts as a reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, the final common pathway for fibrinogen binding that links platelets together. By occupying this receptor, the drug blocks fibrinogen attachment, thereby inhibiting platelet aggregation and thrombus formation during acute coronary events and percutaneous coronary procedures. The inhibition is dose‑dependent and rapidly reversible upon discontinuation, allowing platelet function to recover within hours.

Side Effects

Eptifibatide may be associated with several adverse reactions, ranging from frequent, mild events to rare but serious complications.

Common Side Effects

Bleeding at catheter insertion sites: mild oozing that usually stops with pressure.
Minor bruising or hematoma: localized skin discoloration without significant blood loss.
Mild thrombocytopenia: slight drop in platelet count that resolves after therapy.
Nausea or vomiting: transient gastrointestinal discomfort.
Headache: mild to moderate intensity, often self‑limiting.

Serious or Rare Side Effects

Severe or uncontrolled bleeding: may require transfusion or surgical intervention.
Acute profound thrombocytopenia: platelet count falls below 20,000/µL, increasing hemorrhage risk.
Allergic reactions including anaphylaxis: rash, swelling, respiratory distress necessitating emergency care.
Paradoxical myocardial infarction: rare clot formation despite antiplatelet therapy.

Precautions & Warnings

When using Integrilin, clinicians should observe several precautionary measures to minimize risks and ensure safe therapy.

Bleeding risk: monitor patients for signs of hemorrhage, especially at invasive sites.
Thrombocytopenia: obtain baseline platelet count and repeat monitoring during treatment.
Renal impairment: adjust use or avoid in severe renal dysfunction due to altered clearance.
Concurrent anticoagulants: evaluate cumulative bleeding risk when combined with heparin or warfarin.
Hypersensitivity: discontinue immediately if an allergic reaction such as rash or anaphylaxis occurs.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Eptifibatide can interact with other agents that affect hemostasis or share metabolic pathways, requiring careful management.

Major Interactions (Avoid)

Heparin: concurrent use markedly increases the risk of major bleeding and may require dose reduction or alternative anticoagulation.
Other glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban): additive antiplatelet activity can lead to severe hemorrhage and should be avoided.

Moderate Interactions (Monitor Closely)

Warfarin: eptifibatide may enhance anticoagulant effect; monitor INR and adjust warfarin dose as needed.
Clopidogrel: combined antiplatelet therapy raises overall bleeding potential; observe for signs of occult bleeding.
Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair platelet function and increase gastrointestinal bleeding risk; use with caution.

Frequently Asked Questions

Integrilin, containing the active ingredient eptifibatide, is employed as an antiplatelet agent in the management of acute coronary syndromes such as unstable angina and non‑ST elevation myocardial infarction, as well as during percutaneous coronary intervention to prevent platelet‑mediated thrombus formation.

Eptifibatide reversibly binds to the platelet glycoprotein IIb/IIIa receptor, blocking the final binding site for fibrinogen. This inhibition prevents platelets from linking together, thereby reducing aggregation and the development of arterial clots during coronary events or interventional procedures.

The dose of Integrilin is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and concurrent therapies. Dosing regimens follow established clinical guidelines and are adjusted according to therapeutic response and safety monitoring.

Safety data for eptifibatide in pregnancy and lactation are limited. The drug should only be used when the potential maternal benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Integrilin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Integrilin (eptifibatide) is a short‑acting, reversible glycoprotein IIb/IIIa inhibitor, offering rapid onset and offset compared with abciximab, which binds irreversibly, and tirofiban, which has a slightly longer half‑life. This profile can be advantageous in procedures requiring tight control of platelet inhibition.

Integrilin must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside the recommended range.

Integrilin is supplied as an injectable solution for intravenous use. It is typically given as an initial bolus followed by a continuous infusion, with the exact rate and duration determined by the treating physician according to the clinical situation.

The most critical safety concerns are severe or uncontrolled bleeding, acute profound thrombocytopenia (platelet count <20,000/µL), and hypersensitivity reactions including anaphylaxis. Prompt recognition and management of these events are essential.

Integrilin is contraindicated in patients with active major bleeding, severe thrombocytopenia, known hypersensitivity to eptifibatide or any component of the formulation, and in those who have had a recent intracranial hemorrhage. Caution is also advised in severe renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.